News


DateTitle
20-12-2016Opsona Therapeutics Ltd. announces preliminary results from ongoing study in second line lower risk myelodysplastic syndrome (MDS) recently presented at the 58th Annual Meeting of the American Society
23-11-2016Opsona Therapeutics Ltd. to present preliminary results from ongoing study in second line lower risk myelodysplastic syndrome (MDS) at the 58th Annual Meeting of the American Society of Hematology
25-10-2016Opsona Therapeutics Ltd. receives orphan designation for myelodysplasticsyndrome (MDS) with OPN-305, a first-in-class monoclonal antibody that blocksToll-Like Receptor 2
22-12-2015Opsona Therapeutics - At the forefront of immunology
02-03-2015Opsona Therapeutics Ltd. commences Part B of phase II study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor renal transplant recipients at high risk of Early Graft Dysfunction
23-02-2015Opsona Therapeutics Ltd. Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof
19-02-2015Opsona Therapeutics Ltd. Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof
26-01-2015Opsona Therapeutics Ltd. initiates a prospective open label Phase I/II study in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) with OPN-305, a First-in Class Monoclonal
10-09-2014New treatment against transplantation complications tested
10-09-2014Why Toll-Like Receptor-2 Has Blockbuster Potential
02-10-2013Opsona Therapeutics Limited raises an additional €3 million (USD 4 million) from Omnes Capital in Series C extension, resulting in a total financing round of € 36 million (USD 48.6 million)
07-05-2013Opsona Therapeutics Ltd. initiates a Phase II Study with OPN-305, a First-in Class Monoclonal Antibody
29-04-2013Opsona Therapeutics Limited raises €33 million (USD 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305
10-12-2012Luke O’Neill has been presented the Royal Irish Academy Gold Medal
20-07-2012Opsona wins Outstanding Achievement Award at Ireland’s Champions of EU Research event
17-04-2012Patent issued for the development of an antibody directed against Toll-like Receptor TLR-2
09-02-2012Opsona Appoints Dr Martin Welschof as CEO
05-07-2011Opsona Therapeutics announces Phase 1 clinical trial of its lead drug
06-05-2011Dr Leon Hooftman appointed Chief Medical Officer as Opsona moves to clinical trials
06-05-2011EU awards €5.9m to Opsona Therapeutics for clinical development of lead drug candidate OPN-305
06-05-2011Opsona Chairman Dr Bernd R. Seizinger becomes Executive Chairman
01-11-2009Opsona appoints CFO and strengthens management team
09-10-2009Opsona Therapeutics founder receives prestigious Boyle Medal
18-05-2009Roche Venture Fund, Enterprise Ireland commit €3.3m to Opsona Series B financing
04-03-2009Opsona and Lonza sign manufacturing agreement for monoclonal antibody OPN-305
22-02-2009CSL Ltd and Opsona in R&D collaboration targeting infectious diseases and oncology
18-02-2009Opsona Therapeutics closes €18m funding
02-02-2009Antitope Ltd and Opsona announce successful Composite Human Antibody project
24-11-2008Opsona Therapeutics appoints new VP of Research
19-05-2008Opsona CEO is Ernst & Young Entrepreneur of Year finalist
15-05-2008Opsona receives milestone payments under Wyeth collaboration
21-11-2007Opsona Therapeutics in-licenses novel anti-inflammatory molecule from Nestlé
15-03-2006Phylogica and Opsona enter into drug discovery collaboration
13-02-2006Wyeth and Opsona Therapeutics to collaborate on Toll-Like Receptors
24-02-2005Opsona completes €6.6m financing agreement
01-01-2005Latest news